Table 3.

Associations of thyroid function with markers of renal function.

	Subclinical Hyper vs. Euthyroid β (95%-CI)	Overt Hyper vs. Euthyroid β (95%-CI)	Subclinical Hypo vs. Euthyroid β (95%-CI)	Overt Hypo vs. Euthyroid β (95%-CI)
eGFR (CKD-EPI); mL/min	2.86 (1.56; 4.16) *	0.92 (−1.24; 3.08)	−2.85 (−4.47; −1.23) *	−7.98 (−11.76; −4.19) *
eGFR (FAS); mL/min	3.04 (1.57; 4.51) *	1.02 (−1.43; 3.47)	−3.35 (−5.19; −1.51) *	−7.33 (−11.62; −3.03) *
	Odds ratio (95%-CI)	Odds ratio (95%-CI)	Odds ratio (95%-CI)	Odds ratio (95%-CI)
eGFR (CKD-EPI) < 60 mL/min	0.67 (0.45; 0.99) *	1.36 (0.82; 2.27)	0.94 (0.52; 1.67)	2.34 (0.99; 5.56)
eGFR (FAS) < 60 mL/min	0.78 (0.567; 1.09)	0.78 (0.47; 1.28)	0.91 (0.56; 1.48)	2.65 (1.15; 6.07) *
ACR ≥ 30 mg/g	0.94 (0.71; 1.25)	1.17 (0.77; 1.80)	1.35 (0.93; 1.97)	1.34 (0.63; 2.84)

Compared to TSH in the range; CI, confidence interval; * p < 0.05. Estimates are derived from linear (continuous outcomes) and logistic regression (dichotomous outcomes) models adjusted for age, sex, smoking status, intake of thyroid medication, and study. Participants were categorized according to thyroid function status: subclinical hyper (n = 427): low tsh, ft3, and ft4 in the reference range; overt hyper (n = 153): low tsh, ft3, or ft4 increased; subclinical hypo (n = 264): high tsh, ft3, and ft4 in the reference range; overt hypo (n = 47): high tsh, ft3, or ft4 decreased; euthyroid: TSH in the reference range.